Septic Shock - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 92
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S26972815F7EN
Leaflet:

Download PDF Leaflet

Septic Shock - Pipeline Review, H2 2016
Septic Shock - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Septic Shock - Pipeline Review, H2 2016’, provides an overview of the Septic Shock pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Septic Shock and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Septic Shock
  • The report reviews pipeline therapeutics for Septic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Septic Shock therapeutics and enlists all their major and minor projects
  • The report assesses Septic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Septic Shock
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Septic Shock
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Septic Shock Overview
Therapeutics Development
Pipeline Products for Septic Shock - Overview
Pipeline Products for Septic Shock - Comparative Analysis
Septic Shock - Therapeutics under Development by Companies
Septic Shock - Therapeutics under Investigation by Universities/Institutes
Septic Shock - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Septic Shock - Products under Development by Companies
Septic Shock - Products under Investigation by Universities/Institutes
Septic Shock - Companies Involved in Therapeutics Development
Adrenomed AG
Ferring International Center S.A.
Huons Co., Ltd.
InflaRx GmbH
Inotrem S.A.
Lixte Biotechnology Holdings, Inc.
Noxxon Pharma AG
Octapharma AG
Orion Oyj
Peptinov SAS
Pharmazz, Inc.
Spider Biotech
Takeda Pharmaceutical Company Limited
Therashock, LLC
ViiV Healthcare Limited
XImmune AB
Septic Shock - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
3K3A-APC - DRUG PROFILE
Product Description
Mechanism Of Action
R&D Progress
adrecizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aspidasept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BC-1215 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-936559 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTZO-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Sepsis and Septic Shock - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBN-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBN-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HU-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-257 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levosimendan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-6229 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Motrem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXD-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMZ-2010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pooled plasma (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-190 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-056 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selepressin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Septic Shock - Dormant Projects
Septic Shock - Discontinued Products
Septic Shock - Product Development Milestones
Featured News & Press Releases
Sep 13, 2016: Inotrem Successfully Completes Its First Phase I Clinical Trial with Motrem, a TREM-1 Pathway Modulator for the Treatment of Septic Shock
Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery
Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody
Oct 08, 2015: Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan
Jun 16, 2015: Tenax Therapeutics Highlights New Scientific Publication Regarding the Potential Mortality Benefits of Levosimendan in Septic Shock Patients
Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Septic Shock, H2 2016
Number of Products under Development for Septic Shock - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Septic Shock - Pipeline by Adrenomed AG, H2 2016
Septic Shock - Pipeline by Ferring International Center S.A., H2 2016
Septic Shock - Pipeline by Huons Co., Ltd., H2 2016
Septic Shock - Pipeline by InflaRx GmbH, H2 2016
Septic Shock - Pipeline by Inotrem S.A., H2 2016
Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016
Septic Shock - Pipeline by Noxxon Pharma AG, H2 2016
Septic Shock - Pipeline by Octapharma AG, H2 2016
Septic Shock - Pipeline by Orion Oyj, H2 2016
Septic Shock - Pipeline by Peptinov SAS, H2 2016
Septic Shock - Pipeline by Pharmazz, Inc., H2 2016
Septic Shock - Pipeline by Spider Biotech, H2 2016
Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Septic Shock - Pipeline by Therashock, LLC, H2 2016
Septic Shock - Pipeline by ViiV Healthcare Limited, H2 2016
Septic Shock - Pipeline by XImmune AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Septic Shock - Dormant Projects, H2 2016
Septic Shock - Dormant Projects (Contd.1), H2 2016
Septic Shock - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Septic Shock, H2 2016
Number of Products under Development for Septic Shock - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Adrenomed AG
Ferring International Center S.A.
Huons Co., Ltd.
InflaRx GmbH
Inotrem S.A.
Lixte Biotechnology Holdings, Inc.
Noxxon Pharma AG
Octapharma AG
Orion Oyj
Peptinov SAS
Pharmazz, Inc.
Spider Biotech
Takeda Pharmaceutical Company Limited
Therashock, LLC
ViiV Healthcare Limited
XImmune AB
Skip to top


Septic Shock - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 90 pages
Hemorrhagic Shock - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 38 pages
Hemorrhagic Shock - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 37 pages
Septic Shock - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages

Ask Your Question

Septic Shock - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: